Welcome to our dedicated page for Cno Finl Group SEC filings (Ticker: CNO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CNO Financial Group’s SEC disclosures are dense with actuarial tables, reserve calculations and investment schedules—essential data that can overwhelm even seasoned analysts. If you’ve ever wondered where in a 300-page document the risk-based capital ratio or Bankers Life claim reserves are buried, you know the challenge of decoding “CNO SEC filings explained simply.”
Stock Titan solves this problem. Our AI reads every CNO quarterly earnings report 10-Q filing, CNO annual report 10-K simplified, and CNO 8-K material events explained the moment they post to EDGAR, then delivers concise summaries, ratio tables and trend charts. Need CNO insider trading Form 4 transactions or alerts on CNO Form 4 insider transactions real-time? We flag executive stock moves before most screens refresh. Curious about dividends or portfolio shifts? Our AI highlights them while linking directly to the relevant page of the filing, so you can focus on decisions, not document hunts.
Because CNO’s business depends on long-duration liabilities, investors track interest-rate sensitivity, segment margins and statutory capital. Our coverage connects each form to the insight it unlocks: 10-K footnotes reveal credit quality of the 40|86 Advisors portfolio; 10-Q MD&A shows changes in health loss ratios; 8-K breaks down reinsurance transactions; the proxy details CNO proxy statement executive compensation. Use our platform to monitor CNO executive stock transactions Form 4, dive into CNO earnings report filing analysis, and get context for every material event. That’s understanding CNO SEC documents with AI—saving hours and improving clarity.
CNO Financial Group director Mary R. Henderson reported a sale of 6,300 shares of CNO common stock on 08/28/2025. The Form 4 shows the disposition was coded as a charitable donation and carried no cash proceeds (price $0). After the reported transaction, Ms. Henderson beneficially owned 73,460 shares in total, held directly.
The filing is a routine Section 16 disclosure by an insider and lists the transaction executor as Heidi M. Krings, Attorney-in-Fact, with a signature date of 08/29/2025. No options, derivatives, or other compensatory transactions are reported on this form.
Karen J. DeToro, President of the Worksite Division at CNO Financial Group (CNO), reported sales of common stock under a Rule 10b5-1 plan adopted May 6, 2025. The filing shows three separate dispositions on August 13-15, 2025 totaling 25,657 shares sold at weighted average prices of approximately $37.96, with reported per-trade weighted averages of $37.9588, $37.9788 and $37.8481. After these sales the reporting person beneficially owned 41,855 shares. The filing indicates the transactions were made pursuant to an affirmative-defense 10b5-1 plan and that detailed per-price breakdowns can be provided upon request.
CNO Financial Group insider filing (Form 4/A) shows that Karen J. DeToro, President of the Worksite Division and an officer of CNO (ticker: CNO), disposed of 1,417 shares of common stock on 01/02/2025. The shares were surrendered to the issuer to cover required tax withholding on vested restricted stock units, at an indicated price of $37.14 per share. Following the transaction, Ms. DeToro beneficially owned 58,918 shares. The filing is an amendment that corrects the amount disposed and the post-transaction beneficial ownership.
CNO Financial Group, Inc. (CNO) Form 144 reports a proposed sale of 9,228 shares of common stock through Morgan Stanley Smith Barney LLC with an aggregate market value of $349,262.27, based on an approximate sale date of 08/15/2025 on the NYSE. The filing lists total shares outstanding of 96,931,934. The securities were acquired as performance shares on 02/14/2023 (7,479 shares) and as restricted stock on 09/30/2021 (1,749 shares). The filer also reported recent sales: 6,509 shares on 08/14/2025 for $247,203.36 and 9,920 shares on 08/13/2025 for $376,551.30. The notice includes the standard representation regarding material nonpublic information and a broker identification.
Form 144 notice for proposed sale of CNO Financial Group, Inc. securities. The filing reports an intended sale of 3,457 common shares with an aggregate market value of $130,845.38. The shares represent part of outstanding common stock of 96,931,934 and the approximate proposed sale date is 08/15/2025 on the NYSE. The 3,457 shares were acquired from the issuer as restricted stock (1,985 shares, 03/25/2024) and performance shares (1,472 shares, 02/15/2024).
Recent sales by the same person are disclosed: Jeanne Linnenbringer sold a total of 11,282 common shares on 08/13/2025 and 08/14/2025 across four trades, generating gross proceeds of $524,457.40 in aggregate as reported. The filer affirms no undisclosed material adverse information and includes standard Rule 144 and Rule 10b5-1 representations.
Jeanne L. Linnenbringer, Chief Operations Officer of CNO Financial Group (CNO), exercised stock options and sold common stock under a 10b5-1 plan. On 08/13/2025 she exercised 4,420 stock options with a $21.06 exercise price, acquiring 4,420 shares. Those shares and additional holdings were sold under a Rule 10b5-1 trading plan adopted May 5, 2025, with reported sales on 08/13/2025, 08/14/2025 and 08/15/2025 at weighted average prices of about $37.96, $37.9794 and $37.8495 respectively. Reported beneficial ownership fell from 45,583 shares after the option exercise to 30,844 shares after the sales. The filing notes vesting of the options (half vested 02/23/2019 and half 02/23/2020).
Gary C. Bhojwani, Chief Executive Officer and Director of CNO Financial Group, Inc. (CNO), reported multiple gifts of company common stock executed on 08/12/2025. The filing shows disposals by gift: 3,092 shares from personal holdings (reported at $0 per share), 5,904 shares from the Gary C. Bhojwani Revocable Trust (reported at $0), and a further 195,926 shares disposed (listed as a disposal). After the reported transactions, the filing records 698,331 shares beneficially owned following the first disposal, held indirectly. The form is signed by an attorney-in-fact on 08/14/2025. All transactions are labeled as gifts in the explanation.
Form 144 notice for proposed sale of CNO Financial Group, Inc. securities. The filing shows an intended sale of 4,862 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $184,655.84 and 96,931,934 shares outstanding. The approximate date of sale is listed as 08/14/2025 on the NYSE.
The filer reports acquisition details: 1,478 performance shares acquired 02/15/2024 and 3,384 restricted shares acquired 08/09/2024, both from the issuer. The filing also discloses sales during the past three months by Jeanne Linnenbringer totaling 6,420 common shares sold on 08/13/2025 with gross proceeds of $167,782.76 and $75,919.80.
Certain filer and issuer identifying fields (CIK, issuer name, contact details) are not populated in the provided text.
CNO Financial Group Form 144 discloses a proposed sale of common stock: 9,920 shares with an aggregate market value of $376,551.30, to be executed on the NYSE through Morgan Stanley Smith Barney LLC with an approximate sale date of 08/13/2025. The filing records 96,931,934 shares outstanding.
The shares were acquired from the issuer on 02/15/2024 as performance shares and payment is shown as Not Applicable. The filer reports Nothing to Report for securities sold during the past three months and makes the standard representation that they are not aware of undisclosed material adverse information about the issuer.
Form 144 notice for CNO Financial Group (CNO) reports a proposed sale of 6,420 common shares with an aggregate market value of $243,702.56. The shares are to be sold on the NYSE through Morgan Stanley Smith Barney LLC with an approximate sale date of 08/13/2025. Total shares outstanding reported are 96,931,934, giving readers the raw figures needed to assess scale.
The filing shows how the securities were acquired: 2,000 shares were restricted stock granted on 08/09/2024 and 4,420 were from a stock option exercise on 08/13/2025 paid in cash. The filer reports no sales in the past three months.
FAQ
What is the current stock price of Cno Finl Group (CNO)?
What is the market cap of Cno Finl Group (CNO)?
